摩根大通发表内险股报告指,中国财险及中国人民保险集团受惠非寿险承保多年改善,并对比寿险险企有较低投资账本风险,导致两者股价过去四年分别上升1.37及1.7倍,对比恒指同期升8%。该行建议投资者现在获利,并把两者投资评级由“增持”降至“中性”,认为非寿险承保周期已见顶,进一步上行催化剂有限。相反,该行认为内地寿险股正处于每股盈利与派息预期上调周期,偏好中国人寿及中国平安,分别基于每股盈利预测修正及...
Source Link摩根大通发表内险股报告指,中国财险及中国人民保险集团受惠非寿险承保多年改善,并对比寿险险企有较低投资账本风险,导致两者股价过去四年分别上升1.37及1.7倍,对比恒指同期升8%。该行建议投资者现在获利,并把两者投资评级由“增持”降至“中性”,认为非寿险承保周期已见顶,进一步上行催化剂有限。相反,该行认为内地寿险股正处于每股盈利与派息预期上调周期,偏好中国人寿及中国平安,分别基于每股盈利预测修正及...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.